Kymera Therapeutics Inc. (KYMR) saw its stock price surge 5.04% during intraday trading on Thursday, marking a significant rebound in the session.

The rally comes despite the company reporting a wider-than-expected fourth-quarter net loss and revenue that fell short of analyst estimates. However, investor sentiment appeared buoyed by continued analyst confidence and positive updates on the company's clinical pipeline.

Analysts at BTIG and Piper Sandler maintained their Buy and Overweight ratings on the stock, respectively, signaling ongoing belief in the company's long-term prospects. This support likely helped counter the negative initial reaction to the financial results. Furthermore, the company published a corporate presentation detailing progress in its pipeline of oral degrader medicines for immunology, including its lead STAT6 degrader, KT-621, which is in Phase 2b trials for atopic dermatitis and asthma.

The company's business update also highlighted a strong financial position, with $1.6 billion in cash providing a runway into 2029, allowing it to fund operations beyond several key clinical milestones.